



**THE BRACCO GROUP AND SHANGHAI PHARMACEUTICALS HOLDING,
THE SECOND LARGEST CHINESE PHARMACEUTICAL COMPANY,
RENEW THEIR PARTNERSHIP UNTIL 2037**

博莱科集团与中国第二大医药巨头上海医药合作延续至 2037 年

The agreement extends the partnership between Bracco and Sine Pharmaceuticals for an additional 20 years, and further consolidates the Italian company's presence in China. The plan of collaboration will provide new growth opportunities for the Bracco-Sine joint venture in a market undergoing a significant transformation led by the current Chinese health system reform.

该协议的签订使博莱科集团与上药信谊的合作伙伴关系再延续 20 年，同时也进一步巩固了意大利公司在中国的业务发展。在当前中国卫生体制改革所带来的重大机遇下，新一轮的合作必将为博莱科信谊合资公司提供新的增长机会。

Shanghai, 15 December 2016 - The agreement which will extend the partnership between the Bracco Group and the Sine of Shanghai Pharmaceuticals Holding, the second most important Chinese pharmaceutical company, for another twenty years was signed today at Bracco Sine in Shanghai. The renegotiation process began in 2014 and reached its first major stage at the end of 2015, when both companies expressed the wish to continue their fruitful collaboration for the coming years.

2016 年 12 月 15 日，博莱科集团与中国第二大医药巨头上海医药旗下的上海上药信谊药厂有限公司在博莱科信谊总部签署合作协议，合资关系延续 20 年。新一轮合作谈判始于 2014 年，并在 2015 年年底达到第一个主要阶段，两家公司均表示希望在未来几年继续开展富有成效的合作。

The agreement, signed by **Fulvio Renoldi Bracco**, Head of the Global Business Unit Imaging at Bracco and Mr. **Gu Haoliang**, Vice President of Shanghai Pharmaceuticals Holding and General Manager of Sine Pharma, took place in the presence of the Italian Ambassador to the People's Republic of China, **Ettore Francesco Sequi**, the Italian Consul General in Shanghai, **Stefano Beltrame**, and the Italian Trade Commissioner of the ICE (Agency for the promotion abroad and globalization of Italian enterprises) in Shanghai, Claudio Pasqualucci, the government officials from SFDA (Shanghai Food and Drugs Administration) and PDMSA (Pudong Marketing Supervision Administration), the Chairman of the Board of Shanghai Pharmaceuticals Holding, **Zhou Jun**, the President and Executive Director of Shanghai Pharmaceuticals Holding, **Cho Man**.

该协议由博莱科集团全球造影剂业务负责人 **Fulvio Renoldi Bracco**，以及上海医药副总裁、上药信谊的代表顾浩亮先生共同签署。意大利驻华大使 **Ettore Francesco Sequi**、意大利驻上海总领事 **Stefano Beltrame**、中国 ICE 商务特派员（负责为意大利企业做海外推广和全球化的机构）**Claudio Pasqualucci**、上海食品药品监督管理局领导、上海市场监督管理局领导以及上海医药董事长周军先生、上海医药执行董事兼总裁左敏先生见证了该过程。

"Today's signing is an important step for the future of the Bracco Group," stated **Fulvio Renoldi Bracco**. "The renewal of the joint venture between Bracco and Sine Pharmaceuticals until 2037 further consolidates our presence in one of the most geographically strategic areas for the Group. In fact, China has already this year become the second most important market for us regarding turnover. The deal provides for a greater focus on the development of local needs, on the one hand continuing on the path of consolidation in X-ray/Computed Tomography and Magnetic Resonance imaging modalities; on the other, working in the area of contrast media for ultrasound, an especially innovative and potentially far-reaching imaging modality. This collaboration," concludes **Fulvio Renoldi Bracco**, "will provide Bracco Sine with new growth opportunities in a market undergoing a significant transformation led by the current Chinese health system reform. Contributing to China's growth is an honor for an Italian company."

“今天的签约对博莱科集团未来的发展来说是一个重要的里程碑” **Fulvio Renoldi Bracco** 这样说。“博莱科集团与上药信谊共同投资的合资公司续约至 2037 年，这进一步巩固了合资公司在整个博莱科集团内部最重要的区位优势地位。事实上，今年中国已经成为了博莱科集团全球营业额第二大的市场。本次合作提供了更多关注于本地需求的发展机会，一方面继续巩固在 X 射线、计算机断层摄影以及磁共振成像模态方向的发展，另一方面，在极具创新及有深远影响的造影剂及超声领域进行进一步合作”。 **Fulvio Renoldi Bracco** 总结说：“新的合作计划将为博莱科信谊合资公司在当前中国卫生体制改革所带来的重大机遇下提供新的增长机会。意大利总部也非常荣幸并且愿意继续对中国的业务增长进行投资。”

The Bracco Sine joint venture, with Italian majority, was launched in 2001. Since that moment, the partnership has grown rapidly, reaching more than 300 employees and with a manufacturing site located in Pudong (Shanghai), where the most cutting-edge Italian technologies are utilized in the production of contrast media for diagnostic imaging, in the diagnostic modalities of X-ray/Computed Tomography, Magnetic Resonance and Ultrasound Imaging.

博莱科信谊合资公司成立于 2001 年，意大利方占大股东。从合资公司成立伊始，双方合作伙伴关系迅速发展，员工人数超过 300 人，生产基地位于上海浦东新区，其中最先进的核心技术是引入了意方的造影成像技术，用于诊断成像、诊断 X 射线及计算机断层扫描、磁共振以及超声成像。

Bracco Group

Founded in 1927, the Bracco Group is one of the world's leading companies in the diagnostic imaging. It has around 3,400 employees and annual total consolidated revenues of over 1,3 billion euros, of which 81% from international sales, and it is present worldwide. The Company operates in 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. In the Research and Development area, the company invests approximately 9% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 1,800 patents. Bracco Imaging offers a products, injectors and solutions portfolio for all diagnostic applications: X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. Imaging agents are pharmaceutical products aimed at supporting diagnosis and monitoring of various pathologies. The Bracco diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by Acist Medical Systems.

SINE Pharma

Sine was founded in 1916 in Shanghai. The Company's principal business covers pharmaceutical R&D, manufacture, distribution and retailing. Sine is a wholly-owned holding company by Shanghai Pharmaceuticals Holding Co., Ltd ("SPH"), which is one of the biggest pharmaceutical groups in China and was listed in both A+H stock market. Sine owns 9 industrial manufacture, 3 commercial sales



companies, 1 purchasing company, 1 independent R&D Center and 2 JVs. National sales network covers more than 30 provinces, municipalities and autonomous regions, over 150 prefecture-level cities. Establish the Partnerships with more than 1200 Key Clients. Terminal Sales extends to more than 50000 hospitals. Professional & Qualified Sales Force with more than 1500 people.

信谊品牌，始创于 1916 年，是目前全国化学制剂行业中品种最多、剂型最全，集制造、研发、分销及零售于一体的综合性制药企业。目前由中国最大的制药企业之一上海医药集团股份有限公司（A+H 股上市）全资控股。信谊旗下拥有 9 家工业企业，3 家商业公司，1 家采购中心，1 个独立的研发中心以及 2 家合资公司。销售网络辐射全国 30 多个省、市、自治区 150 多个地级市，与国内 1200 余家重点销售客户建立了合作伙伴关系，药品终端延伸至 50000 家医院，拥有 1500 多人的高素质、专业化终端销售队伍。